Manufacturing News of Note—Aurobindo gets 2 483s; Catalent to make BeiGene drug

stocks
(Pixabay)

> The FDA recently posted two Form 483s issued to India’s Aurobindo in October; one for a sterile facility and one for an API facility. 

> CDMO Catalent has been tapped by China's BeiGene, to manufacture its immuno-oncology drug Brukinsa. Release 

> South Korea and Singapore have signed an agreement to work together and share information GMP inspections. Story 

> Ingredient supplier Barentz says that private equity firm Cinven has made an investment that will allow it to expand. Story 

Suggested Articles

Mylan recalls one lot of the injectable antibiotic daptomycin after discovering particles in a single-dose vial.

Lupin Pharmaceuticals pulled all lots of its extended-release diabetes drug metformin amid carcinogen contamination concerns.

Novartis and Civica Rx are patterning up to shore up supply of six key generic injectables used in acute care settings in hospitals.